Genetic Breakthrough: Indian Scientists Unveil Unique Driver of Oral Cancer in Women

Spread the Message

Read Time:3 Minute, 29 Second

BENGALURU — In a landmark development for precision oncology, a team of Indian scientists has identified a unique genetic mutation responsible for aggressive oral cancers in women, challenging the long-held “one-size-fits-all” approach to cancer treatment. The findings, published in the prestigious journal Clinical and Translational Medicine, shed light on why oral cancer manifests differently in women and offers new hope for targeted therapies.

The collaborative study, led by the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru, focused specifically on the genetic underpinnings of oral squamous cell carcinoma (OSCC) in female patients—a demographic often underrepresented in global cancer research.

The “Kaddipudi” Connection

India bears a staggering 40% of the global burden of oral cancer. While tobacco smoking is a primary culprit in men, the disease in Indian women is frequently linked to the smokeless tobacco habit known as chewing “Kaddipudi” (tobacco-infused betel quid), particularly in southern and northeastern regions.

Researchers from JNCASR and the National Institute of Biomedical Genomics (NIBMG), Kalyani, partnered with clinicians from the Sri Devraj Urs Academy of Higher Education and Research (SDUAHER) in Kolar, Karnataka, to study female patients with this specific regional habit.

“While the disease is widely studied in men, oral cancer in women has often remained under the radar,” said Professor Tapas K. Kundu of JNCASR, who led the study. The research aimed to decode why these cancers are often disproportionately aggressive and lethal in women.

Unlocking the Genetic Code: CASP8 vs. TP53

Using cutting-edge whole-exome sequencing on paired tumor and blood samples, the team identified significantly mutated genes in the female cohort. The results revealed a critical distinction:

The Male Profile: In men, oral cancer is predominantly driven by mutations in the TP53 gene.
The Female Profile: In the female cohort, researchers discovered that the CASP8 gene acts as a unique, potent driver mutation.

While TP53 mutations were also present, the study found that the co-occurrence of TP53 and CASP8 mutations creates a “lethal cocktail,” leading to a markedly aggressive form of the disease. CASP8 is traditionally known as a tumor suppressor gene involved in programmed cell death (apoptosis), but in this context, its mutation appears to hijack the cell’s machinery to promote tumor growth.

AI Reveals Hidden Immune Patterns

Beyond genetics, the team employed artificial intelligence (deep learning) to analyze digital images of the tumor tissues. This high-tech analysis uncovered two distinct subgroups of female patients based on the immune response within the tumor microenvironment.

This finding is significant because it suggests that oral cancer in women is not a monolith; different patients may require drastically different treatment strategies based on their specific immune profile.

Implications for Public Health and Treatment

The identification of CASP8 as a female-specific biomarker could revolutionize how oral cancer is diagnosed and treated in India. Currently, treatment protocols are largely standardized. This research paves the way for personalized medicine, where doctors could screen female patients for CASP8 mutations to predict disease aggressiveness and tailor aggressive therapies accordingly.

“This groundbreaking study sets a new benchmark in cancer research,” the Ministry of Science and Technology stated in a release. “It not only highlights the urgent need to include more women patients in biomedical research but also provides a roadmap for personalized medicine.”

Limitations and Future Directions

While the findings are promising, the study was conducted on a relatively small cohort (N=38) from a specific region. The researchers emphasized that these results need validation in larger, multi-centric studies across India to confirm their universal applicability. The team is now entering the next phase of research to map the precise molecular mechanisms by which the CASP8 mutation drives cancer in the presence of TP53 alterations.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.